Live Chat Software

Sponsorship enquiry

Early and Managed Access Programmes 2018 Full Agenda

Early and Managed Access Programmes 2018 Full Agenda

Download the 2018 agenda for full speaker and session information!

Early & Managed Access Programmes Agenda - spex

Join the Early and Managed Access Programmes forum to explore topics in: Preparing for your Early Access Programmes with effective planning and a water-tight logistical strategy, navigating the complex and diverse regulatory and ethical landcape, the debate surrounding Real World Data, optimising your clinical operations and post-trial access.

On the 5-7th November 2019, over three full days of case-studies, interactive discussions and workshops, industry leaders from companies such as Janssen, Bristol-Myer's Squibb, Novartis, Vifor Pharma and Zogenix will discuss their EMAP strategies with input from Patient Advocacy Groups and Regulatory Professionals from across Europe and the US.

Download the 2019 agenda for a look at who is speaking and the topics to be discussed!

Trends & Investment Report: Early & Managed Access Programmes

Trends & Investment Report: Early & Managed Access Programmes

The number of named patient requests has increased over time due to patients, advocacy groups and physicians becoming increasingly well informed on the developmental pipelines of pharma and biotechs across the world. To keep up with rising demands, pharma companies have had to invest heavily in Early Access Programmes to meet the unmet medical needs of patients who have exhausted all other roots of treatment.

Ahead of the Early and Managed Access Programmes Forum taking place this November in London, Pharma IQ have created an infographic detailing the industries outsourcing challenges and investment plans to help vendors navigate through this ever-changing market landscape

Download our infographic to get the latest insights into:

  • The level at which pharma companies are running an active programme in the next 12 months.
  • The current capability of pharma companies to conduct an Early Access Programme in-house from end-to-end.
  • Which aspects of Early Access Programme require the support of external solution providers.
  • How much pharma companies are looking to invest into expanded and managed access programmes in the next 12-24 months.